Coagulation indicators in chronic stable effort angina and unstable angina: Relationship with acute phase reactants and clinical outcome

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 3, 2002, Pages 247-255

  Fiotti, Nicola ^a   Di Chiara, A ^a   Altamura, N ^a   Miccio, M ^a   Fioretti, P ^a   Guarnieri, G ^a   Giansante, C ^a  

^a Istituto di Patologia Medica   (Italy)

Author keywords

C reactive protein; Fibrin fibrinogen degradation products; Myocardial infarction; Myocardial revascularization; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; D DIMER; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NITRIC ACID DERIVATIVE; PROTEIN PRECURSOR; PROTHROMBIN; TROPONIN I;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD CLOTTING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE-PHASE PROTEINS; AGED; ANGINA PECTORIS; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CHRONIC DISEASE; DEATH, SUDDEN, CARDIAC; EXERTION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PEROXIDASES; PROGNOSIS; PROTEIN ISOFORMS; PROTHROMBIN; RISK FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 0036526498     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200204000-00011     Document Type: Article

References (54)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people
3. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)
4. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris
5. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina
6. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function
7. Lack of correlation between activation of hemostatic mechanism and inflammation in unstable angina pectoris
8. The prognosis value of C-reactive protein and serum amyloid A protein in severe unstable angina
9. Increased levels of Interleukin (IL)-1RA and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
10. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
11. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris
12. Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease
13. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease
14. Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction
15. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris
16. Haemostatic variables in patients with unstable angina
17. Activation markers of coagulation and fibrinolysis: Alterations and predictive value in acute coronary syndromes
18. Myocardial infarction refined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction
19. Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: Relationships with other cardiovascular risk factors
20. Coronary artery disease: Pathogenesis and acute coronary syndromes
21. Plaque disruption and thrombosis: Potential rote of inflammation and infection
22. Angiographic findings in patients with refractory unstable angina according to troponin T status
23. Cardiac markers: Present and future
24. Biochemical markers of cardiac damage: From traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM)
25. Strategies for clinical assessment of patients with suspected acute coronary syndromes
26. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction
27. Relationship of cardiac troponin T and procoagulant activity in unstable angina
28. Increased plasma levels of fibrinogen in acute and chronic ischemic coronary syndromes
29. C-Reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndromes
30. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
31. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease
32. C-reactive protein
33. C-reactive protein in ischemic stroke: An independent prognostic factor
34. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
35. Elevated levels plasmin-alfa2 antiplasmin complexes in unstable angina
36. Early risk stratification of unstable angina/non-Q myocardial infarction: Biochemical markers of coronary thrombosis
37. Correlation between coronary morphology and molecular markers of fibrinolysis in unstable angina pectoris
38. New tricks for old dogs: Nonthrombotic effects of thrombin in vessel wall biology
39. The biology of prothrombin
40. Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy
41. The scientific basis for selection of measures of thrombogenicity
42. Assessment of hypercoagulable states by measurement of activation fragments and peptides
43. Thrombus precursor protein (TpP): Marker of thrombosis early in the pathogenesis of myocardial infarction
44. The use of thrombus precursor protein, D-dimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism
45. C-Reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: Are inflammation and fibrin turnover linked in pathogenesis?
46. D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain
47. Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: In-hospital course and relationship with recurrent angina at rest
48. Haemostatic risk factors for cardiovascular diseases
49. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis
50. Discrepancy between latex and ELISA D-dimer values in sepsis may be caused by human neutrophil elastase
51. D-Dimer tests detect both plasmin and neutrophil elastase derived split products
52. Thrombosis-related markers in unstable angina pectoris
53. Characterization of stromelysin 1 (MMP-3), matrilysin (MMP-7), and membrane type 1 matrix metalloproteinase (MT1-MMP) derived fibrin(ogen) fragments D-dimer and D-like monomer: NH2-terminal sequences of late-stage digest fragments
54. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes